Stockscreener 앱 받기
22.43
2.75%
0.635
전일 마감가:
$21.79
열려 있는:
$21.89
하루 거래량:
796.36K
Relative Volume:
0.20
시가총액:
$2.35B
수익:
$2.48B
순이익/손실:
$-57.96M
주가수익비율:
-29.56
EPS:
-0.7585
순현금흐름:
$-453.97M
1주 성능:
+5.96%
1개월 성능:
+1.77%
6개월 성능:
+68.09%
1년 성능:
-81.21%
1일 변동 폭
$21.60
$22.60
1주일 범위
$20.10
$22.60
52주 변동 폭
$10.41
$120.05
사렙타 테라퓨틱스 Stock (SRPT) Company Profile
명칭
Sarepta Therapeutics Inc
전화
617-274-4000
주소
215 FIRST STREET, CAMBRIDGE, MA
SRPT을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
SRPT
Sarepta Therapeutics Inc
|
22.40 | 2.28B | 2.48B | -57.96M | -453.97M | -0.7585 |
|
VRTX
Vertex Pharmaceuticals Inc
|
466.58 | 118.58B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
753.55 | 79.40B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
830.63 | 51.18B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
363.38 | 48.88B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
341.67 | 37.49B | 4.98B | 69.59M | 525.67M | 0.5197 |
사렙타 테라퓨틱스 Stock (SRPT) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-09 | 개시 | Wedbush | Outperform |
| 2025-11-05 | 업그레이드 | Mizuho | Neutral → Outperform |
| 2025-09-22 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2025-07-29 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2025-07-29 | 개시 | Bernstein | Mkt Perform |
| 2025-07-29 | 재확인 | H.C. Wainwright | Sell |
| 2025-07-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2025-07-29 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2025-07-28 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2025-07-25 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2025-07-24 | 개시 | Citigroup | Sell |
| 2025-07-23 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2025-07-22 | 다운그레이드 | Barclays | Overweight → Equal Weight |
| 2025-07-21 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-07-21 | 다운그레이드 | Leerink Partners | Outperform → Market Perform |
| 2025-07-21 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2025-07-21 | 다운그레이드 | Needham | Hold → Underperform |
| 2025-07-21 | 다운그레이드 | UBS | Buy → Neutral |
| 2025-07-18 | 다운그레이드 | Needham | Buy → Hold |
| 2025-06-20 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
| 2025-06-18 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2025-06-17 | 개시 | Wolfe Research | Peer Perform |
| 2025-06-16 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2025-06-16 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2025-06-16 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2025-06-16 | 다운그레이드 | H.C. Wainwright | Neutral → Sell |
| 2025-06-16 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-06-16 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2025-06-06 | 업그레이드 | Scotiabank | Sector Perform → Sector Outperform |
| 2025-05-08 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-11 | 개시 | Wells Fargo | Overweight |
| 2025-04-02 | 업그레이드 | H.C. Wainwright | Sell → Neutral |
| 2025-03-31 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2025-02-11 | 개시 | Deutsche Bank | Hold |
| 2024-11-27 | 재확인 | Needham | Buy |
| 2024-11-25 | 개시 | H.C. Wainwright | Sell |
| 2024-11-07 | 업그레이드 | Cantor Fitzgerald | Neutral → Overweight |
| 2024-10-21 | 개시 | Jefferies | Buy |
| 2024-10-10 | 재개 | Raymond James | Outperform |
| 2024-07-29 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-06-26 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2024-05-31 | 개시 | Piper Sandler | Overweight |
| 2024-05-28 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-05-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-01-31 | 개시 | BMO Capital Markets | Outperform |
| 2023-12-13 | 재개 | Citigroup | Buy |
| 2023-12-12 | 개시 | Deutsche Bank | Buy |
| 2023-11-21 | 개시 | Wedbush | Outperform |
| 2023-10-31 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2023-10-31 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-06-23 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2023-04-26 | 개시 | SMBC Nikko | Outperform |
| 2023-04-04 | 개시 | Citigroup | Buy |
| 2023-03-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2022-12-22 | 재확인 | BTIG Research | Buy |
| 2022-12-16 | 업그레이드 | UBS | Neutral → Buy |
| 2022-04-04 | 재개 | Cantor Fitzgerald | Overweight |
| 2022-01-05 | 재확인 | Needham | Buy |
| 2021-12-09 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-11-05 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2021-09-15 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2021-08-05 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2021-06-15 | 개시 | BTIG Research | Buy |
| 2021-04-26 | 재개 | Credit Suisse | Neutral |
| 2021-01-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-01-11 | 다운그레이드 | UBS | Buy → Neutral |
| 2021-01-08 | 다운그레이드 | JP Morgan | Overweight → Underweight |
| 2021-01-08 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-01-08 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2020-11-11 | 개시 | Berenberg | Hold |
| 2020-10-28 | 개시 | UBS | Buy |
| 2020-08-25 | 개시 | Raymond James | Outperform |
| 2020-08-20 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2020-03-31 | 개시 | Mizuho | Buy |
| 2019-11-01 | 개시 | Guggenheim | Buy |
| 2019-08-21 | 재확인 | Needham | Buy |
| 2019-07-09 | 재확인 | Morgan Stanley | Overweight |
| 2019-07-01 | 재확인 | RBC Capital Mkts | Outperform |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-11 | 재확인 | Credit Suisse | Outperform |
| 2018-10-12 | 개시 | Bernstein | Outperform |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-09-26 | 재확인 | RBC Capital Mkts | Outperform |
| 2018-09-14 | 재개 | BofA/Merrill | Buy |
| 2018-09-06 | 개시 | Credit Suisse | Outperform |
| 2018-08-01 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2018-06-21 | 재확인 | Robert W. Baird | Outperform |
| 2018-06-20 | 재확인 | Needham | Buy |
| 2018-06-19 | 재확인 | H.C. Wainwright | Buy |
모두보기
사렙타 테라퓨틱스 주식(SRPT)의 최신 뉴스
Wedbush Raises Price Target for Sarepta Therapeutics (SRPT) to $34 | SRPT Stock News - GuruFocus
Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Expected to Rise, Wedbush Analyst Says - MarketBeat
Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Raises Target Price to $34 - 富途资讯
Energy Moves: What is the long term forecast for Sarepta Therapeutics Inc stock - baoquankhu1.vn
2 Beaten-Down Stocks That Could Sink Even More in 2026 - Finviz
Sarepta and Teladoc Face Major Challenges, Stock Outlook Dim - Intellectia AI
Sarepta Therapeutics and Teladoc Health Face Major Challenges, 2026 Outlook Dismal - Intellectia AI
2 Beaten-Down Stocks That Could Sink Even More in 2026 - The Motley Fool
Gene Therapy Market Innovations and Key Players: Biogen, - openPR.com
Profit Review: How volatile is Sarepta Therapeutics Inc. stockJuly 2025 Market Mood & Free Verified High Yield Trade Plans - baoquankhu1.vn
Sarepta Wins FDA Approval To Begin Study On Reducing Liver Injury Risk With Elevidys - MSN
Liquidity Mapping Around (SRPT) Price Events - Stock Traders Daily
Anticipation of a possible new clinical trial has us holding on to hope - huntingtonsdiseasenews.com
Why Sarepta Therapeutics (SRPT) Is Down 11.3% After Elevidys Safety Setback And Revenue MissAnd What's Next - Yahoo Finance
Has Sarepta Therapeutics (SRPT) Fallen Too Far After 82% One-Year Share Price Drop? - Yahoo Finance
Sarepta Preliminary Results: Not What The Market Wanted To Hear (NASDAQ:SRPT) - Seeking Alpha
Will KROS Stock's Restructuring Efforts Reap Rewards for Investors? - The Globe and Mail
Sarepta Therapeutics: Is Elevidys A Bust? (NASDAQ:SRPT) - Seeking Alpha
Is Sarepta Therapeutics Inc stock trending bullishJuly 2025 Analyst Calls & Weekly Top Gainers Trade List - baoquankhu1.vn
Sentiment Recap: Can Ramaco Resources Inc withstand a market correctionJuly 2025 Opening Moves & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
A Look At Sarepta Therapeutics (SRPT) Valuation After Elevidys Safety Setbacks And 2025 Revenue Miss - Sahm
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Sarepta Therapeutics' (SRPT) "Sell" Rating Reiterated at HC Wainwright - MarketBeat
Sarepta shares cut to $0 at H.C. Wainwright - MSN
H.C. Wainwright reiterates Sell rating on Sarepta Therapeutics stock By Investing.com - Investing.com Canada
SRPT: Today's Analyst Ratings and Price Target Update | SRPT Sto - GuruFocus
Forecasting The Future: 8 Analyst Projections For Sarepta Therapeutics - Benzinga
Sarepta (SRPT) Faces Challenges with Elevidys Sales Performance - GuruFocus
Mizuho reiterates Outperform rating on Sarepta stock, maintains $26 target By Investing.com - Investing.com UK
Analysts Have Conflicting Sentiments on These Healthcare Companies: Establishment Labs Holdings (ESTA), Sarepta Therapeutics (SRPT) and Insmed (INSM) - The Globe and Mail
Analyst Downgrade: Is Sarepta Therapeutics Inc stock heavily shorted2025 Key Lessons & High Accuracy Trade Signal Alerts - baoquankhu1.vn
After Mortality-Marred Year, Sarepta Looks Ahead to Catalyst-Rich 2026 - BioSpace
Sarepta Therapeutics (NASDAQ:SRPT) Shares Down 6.7%What's Next? - MarketBeat
Sarepta falls after gene therapy Elevidys misses estimates - The Boston Globe
SRPT: Entering 2026 with strong finances, new data, and major pipeline and regulatory milestones ahead - TradingView — Track All Markets
SRPT Sees Potential Turnaround Despite Soft Q4 Sales - GuruFocus
SRPT Stock Tumbles 12% On Lackluster Preliminary Revenue Numbers Due To Elevidys Safety Concerns - Stocktwits
Sarepta reconfirms yearly sales floor for Elevidys of $500.0 mln - marketscreener.com
SRPT: Entering 2026 with strong financials, expanded therapy reach, and key clinical milestones ahead - TradingView — Track All Markets
Sarepta Falls After Gene Therapy Elevidys Misses Estimates - Bloomberg.com
Sarepta (SRPT) Reports Strong 2025 Revenue Growth and Financial Position - GuruFocus
Sarepta Therapeutics (SRPT) Reports Lower Than Expected Revenue for 2025 - GuruFocus
Sarepta (SRPT) Shares Decline Following Q4 Revenue Announcement - GuruFocus
Sarepta Preliminary Q4, 2025 Net Product Revenue Miss Estimates; Shares Fall - marketscreener.com
Gold, Silver Spike To Record Highs As Fed Independence Falters: What's Moving Markets Monday? - Benzinga
Sarepta Therapeutics Q4 prelim net product revenue misses estimates - TradingView — Track All Markets
Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues - The AI Journal
Sarepta reports $1.86 billion in 2025 product revenue - StreetInsider
Market Outlook: What is Sarepta Therapeutics Incs market positionJuly 2025 Gainers & Smart Swing Trading Alerts - baoquankhu1.vn
Sarepta Therapeutics (SRPT) Stock Analysis: Navigating Through Challenges Amidst a Promising Biotech Future - DirectorsTalk Interviews
Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
사렙타 테라퓨틱스 (SRPT) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.42%
1.57%
자본화:
|
볼륨(24시간):